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Abstract Severe combined immune deficiency (SCID) is a
fatal primary immunodeficiency usually presenting in the first
months of life with (opportunistic) infections, diarrhea, and
failure to thrive. Hematopoietic stem cell transplantation
(HSCT) and gene therapy (GT) are curative treatment options.
The objective of the study was to assess the morbidity, mor-
tality, and diagnostic and therapeutic delay in children with
SCID in the Netherlands in the last 15 years. These data may
help to judge whether SCID should be considered to be in-
cluded in our national neonatal screening program. In the pe-
riod 1998–2013, 43 SCID patients were diagnosed in the
Netherlands, 11 of whom were atypical SCID (presentation
beyond the first year). The median interval between the first
symptom and diagnosis was 2 months (range 0–1173
months). The total mortality was 42 %. In total, 32 patients
were treated with HSCT of whom 8 were deceased. Nine
patients died due to severe infectious complications before
curative treatment could be initiated.
Conclusion: Because of a high mortality of patients with
SCID before HSCT could be initiated, only a national new-
born screening program and pre-emptive HSCTor GTwill be
able to improve survival of these patients.
BWhat is known^
• SCID is a fatal disease if a curative hematopoietic stem cell
transplantation cannot be performed in time.
• Newborn screening for SCID enables early diagnosis in the
asymptomatic phase.
BWhat is new^
• Nine out of 43 SCID patients in the Netherlands died due to severe
infectious complications before curative treatment could be initiated.
• Only newborn screening and pre-emptive curative therapy will improve
survival of children with SCID in the Netherlands.
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Introduction
Severe combined immune deficiency (SCID) is a life-
threatening primary immunodeficiency usually presenting in
the first months of life with (opportunistic) infections,
protracted diarrhea, and failure to thrive [11]. Patients with
SCID are highly susceptible to severe and recurrent infections
and usually do not survive infancy unless provided with im-
mune reconstituting treatments, such as hematopoietic stem
cell transplantation (HSCT), PEG-ADA, or gene therapy
(GT) [11]. Although infections are common in the pediatric
population, an immunodeficiency such as SCID should be
suspected if infections are recurrent, severe, or caused by an
opportunistic pathogen.
The immunodeficiency in SCID patients is characterized
by severe defects in cellular and humoral immunity. The hall-
mark is the absence of T cells, with a primary or secondary
dysfunction of B cells, leading to hypogammaglobulinemia.
Different pathophysiological mechanisms cause absence or
dysfunction of T cells, depending on the genetic defect. If the
genetic defect affects the development of T cells as well as B
cells, the disease is classified as T–B− SCID. If only T cells
are affected, with a secondary dysfunction of B cells, patients
are characterized as T–B+ SCID. Multiple genetic defects in
more than 30 different genes can cause SCID, and another 30
genes can cause other forms of T cell lymphopenia.[1]
Reduced thymopoiesis can be diagnosed in newborn dried
blood spots by high-throughput analysis of T cell receptor
excision circles (TRECs), enabling neonatal screening for
SCID.[4, 8, 10]. Newborn screening for SCID has been intro-
duced with success in parts of the USA [7]. The Clinical and
Laboratory Standards Institute (CLSI) recently published an
international guideline to use newborn bloodspots for SCID
screening by measurement of TRECs [6]. Subsequent lym-
phocyte immunophenotyping and genetic analysis can con-
firm the diagnosis of SCID in case low TRECs and T cell
lymphopenia are detected.
The aim of this study was to determine if SCID is a suitable
candidate for implementation in the newborn screening pro-
gram in the Netherlands [12]. Therefore, we investigated the
presenting symptoms, morbidity, delay in diagnosis and treat-
ment, and the mortality of all SCID patients over the last
15 years in the Netherlands.
Material and methods
In this retrospective cohort study, all SCID patients who were
born in the Netherlands between January 1998 and January
2013 (n=43) were included. SCID patients who underwent
HSCT were selected from the European Group for Blood
and Marrow Transplantation (EBMT) and from the National
Registry as part of the European Society for immunodefi-
ciencies (ESID) databases. The other patients were identified
by reviewing medical records and local patient lists in each
tertiary referral center for clinical pediatric immunology.
Detailed information about HSCT treatment regimens was
collected in the LUMC and UMC Utrecht (HSCT centers in
the Netherlands).
Data collection included general characteristics, family his-
tory, consanguinity, diagnosis, morbidity (type of infections,
frequency and severity of infections, and other symptoms like
autoimmunity and failure to thrive), laboratory data,
(antimicrobial) treatments, and mortality. In addition, we ex-
plored the delay between date of birth, date of first symptoms
(FS), date of diagnosis, and date of therapy or death. Atypical
SCID was defined as diagnosed >1 year after birth. Typical
SCID was defined as diagnosed <1 year after birth. Data were
collected in an anonymized way. Ethical approval was given
by institutional review board.
Differences in patient groups were analyzed using chi-
square analyses. All analyses were performed using software
program SPSS 21.0 (SPSS Inc., Chicago, IL, USA).
Results
From 1998–2013, 43 patients with SCID (23 boys and 20
girls) were identified in the Netherlands. On a total population
of ~180,000 newborns/year, the incidence in this period was
approximately 1:63,000. Eleven patients were diagnosed with
an atypical form of SCID. In 11 patients, consanguinity was
present. Patient characteristics, immunophenotyping, and ge-
netics are described in Table 1 and Fig. 1.
Median follow-up of patients was 66 months (range 1–198
months). Figure 2 shows the intervals between first symptoms
and diagnosis, and diagnosis and treatment. Delay of diagno-
sis (median 27 months after first symptoms) was more pro-
nounced in atypical SCID compared to typical SCID (median
2 months after first symptoms) (Fig. 2).
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Table 1 Patient characteristics
Patient no. Symptoms Gene defect CD3+ CD4+ CD8+ NK+ CD19+ Age at diagnosis (months) Alive HSCT
1 Gastr RAG1 − − − + − 67 − −
2 Resp, Gastr RAG1 − − − + + 37 + +
3 Syst, Resp, Gastr RAG1 − − − + − 6 + +
4 Resp, Gastr RAG1 − − − + − 3 − +
5 Other RAG1 − − − + − 3 + +
6 Syst, Gastr, Other RAG1 + + + − − 2 − −
7 Resp, Other RAG1 − − − − − 11 − −
8 Resp, Gastr RAG1 - − − + − 4 − +
9 Syst, Gastr RAG1 − + − − − 9 − −
10 Syst, Resp, Gastr RAG2 − − − + − 4 + +
11 Other RAG2 − − − + − 5 + +
12 Resp ADA − − − + − 31 − −
13 Other ADA − − − − − 1 + a
14 Gastr ADA − − − − − 1 + +
15 Other ADA + − + + + 1 + +
16 Resp, Gastr ADA − − − − − 1 − −
17 Resp, Gastr IL2RG − − − − − 7 + +
18 Resp, Gastr Other IL2RG + − + + + 64 − +
19 Resp, Gastr IL2RG − − − + + 5 + +
20 Fam IL2RG − − + + + 0 + +
21 Resp IL2RG + − − − + 4 + +
22 Resp IL2RG + − + − + 13 + +
23 Resp IL2RG − − − + + 17 + +
24 Other IL2RG − − − − + 3 + +
25 Fam IL2RG − − − − + 0 − a
26 Resp Artemis − − + − + 157 − +
27 Syst, Resp Artemis − − − − − 75 + +
28 Syst, Other Artemis − − − + − 3 − +
29 Resp PNP − − − − + 19 + +
30 Syst, Resp, Gastr PNP − − − − − 32 + +
31 Other PNP − − − − + 55 + +
32 Other RMRP + − + + + 9 − +
33 Other IL7R − − − − + 6 + +
34 Syst, Gastr IL7R − − − + + 3 + +
35 Fam AK-2 − − − − − 0 + +
36 Syst, Gastr T7q-20q − − − − + 4 + +
37 Resp CD3E − − − + + 1 − −
38 Syst, Resp, Gastr LIG4 − − − − − 8 − −
39 Syst, Resp, Gastr ZAP70 − − − + + 80 + +
40 Resp, Gastr Unknown − − − − − 7 − +
41 Resp Unknown − − − − + 3 − +
42 Gastr Unknown − − − + + 2 − −
43 Other Unknown − − − + + 5 + +
Syst systemic infections (e.g., sepsis), Resp respiratory infections, Gastr gastrointestinal symptoms/failure to thrive, Other skin, other, Fam positive
family history of SCID.
a Gene therapy
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Prior to curative treatment, 22 patients suffered from sys-
temic viral/bacterial infections and 25 suffered from
opportunistic infections. Eleven of 25 patients with opportu-
nistic infections had Pneumocystis jiroveci pneumonia, 8 had
systemic cytomegalovirus infection, and 6 had BCG-itis. Of
these patients, 8 were deceased at a median of 12 days (range
0–88 days) after initial presentation with a fulminant infec-
tions despite antimicrobial treatment (Table 2). There was no
association between delay in diagnosis and mortality (p=
0.269) in the typical SCID patients. In the atypical SCID
group, we found symptoms of auto-immunity (hemolytic ane-
mia) in 5 of 11 patients.
Three patients were diagnosed prior to infectious compli-
cations in the first week of life because of a positive family
history. In one patient, prematurity with lymphopenia and
congenital deafness was present and cartilage-hair-
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Fig. 2 Delay between first symptoms to diagnosis, and diagnosis to
treatment for atypical and typical SCID patients. Boxplots show median
(box) and interquartile range (line)
Table 2 Infections in SCID patients prior to treatment
HSCT or GT
(n=34)a
No HSCT or
GT (n=9)b
p value
Bacterial sepsis 3 8 0.001
Pneumonia
P. jiroveci 9 2
Other 13 6 0.237
Systemic viral infection
Adenovirus 3 1
Cytomegalovirus 5 3
Other 5 0 1.01
BCG-itis/TB 5 1 0.998
Cryptosporidium 2 2 0.189
Pseudomonas 2 1 0.510
HSCT hematopoietic stem cell transplantation, GT gene therapy
a Seven patients suffered from >1 infection
b Five patients suffered from >1 infection
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hypoplasia with SCID was diagnosed. Two of these three
patients underwent HSCT and one patient received gene ther-
apy. This patient was deceased due to secondary malignancy
following initially successful gene transfer [15].
In total, 34 patients received curative treatment, of whom 2
received gene therapy (Fig. 3). Eleven of 24 survivors showed
infectious complications after HSCT and 2 of 24 patients had
allo-reactive complications. Twentyfour of the 32 patients
were successfully transplanted. One ADA SCID patient was
successfully treated with gene therapy.
Discussion
This retrospective analysis of SCID patients in the
Netherlands shows that morbidity and mortality were high.
The incidence may be an underestimation due to non-
diagnosed infants, deceased due to severe infection. The ma-
jority of deaths were associated with severe infections. Given
the fact that early identification newborn screening is feasible,
these data suggest that a significant number of SCID cases can
be cured by early HSCT or gene therapy, preceded by appro-
priate anti-infectious prophylaxis after implementation of
newborn screening for SCID.
The occurrence of the first symptoms of SCID at 2–3
months after birth was comparable with observations of others
[5, 11]. We observed a relatively high proportion of patients
with atypical SCID in our cohort [13]. These patients had
severe infections and high mortality rates. A clinical presen-
tation with milder or non-opportunistic infections and/or auto-
immunity explained the longer delay in diagnosis.
Importantly, our data indicate that even if SCID is diag-
nosed early after the initial presenting symptoms, mortality
cannot be prevented in a considerable proportion of SCID
patients because of a fulminant course of the presenting infec-
tion. Many of these patients were diagnosed with bacterial
sepsis. So, the only way to improve the outcome is to diagnose
these patients by a newborn screening program for SCID be-
fore symptoms occur. The asymptomatic patients who
received HSCT early in life were successfully transplanted,
as described by others [3]. However, in patients surviving until
HSCT, mortality due to pre-HSCT infections was still consid-
erable, in line with other studies [2, 3]. Newborn diagnosis and
early treatment of SCID in the asymptomatic phase improves
the outcome by reduction of infections and improved overall
survival after HSCT [2, 3]. Recently, Pai et al. reported excel-
lent survival rates of 94% in SCID patients transplanted in the
first 3.5 months (n=68) compared to 66 % in patients who
received HSCT after 3.5 months of age (n=172)[9].
Considering the prerequisites for neonatal screening [12],
we showed that in most patients, an early asymptomatic phase
is present, enabling identification in this pre-symptomatic ep-
isode and in good clinical condition. These data support the
idea that newborn screening for SCID will also be useful to
prevent death and severe complications in the Dutch situation
and comparable countries [7].
In conclusion, this study shows a high morbidity and mor-
tality in SCID patients in the Netherlands, irrespective of age
at diagnosis, diagnostic delay and intensive treatment of in-
fections and supportive care preceding HSCT. We further
found a high proportion of patients with atypical presentation
of SCID, which warrants a high level of suspicion in patients
with infections and immune dysregulation. Because most pa-
tients had an asymptomatic phase and because early HSCT
has a good prognosis in such patients, our findings strongly
support the implementation of newborn screening for SCID in
the Netherlands.
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